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Abstract
Background: Differences could exist in the likelihood of asthma attacks in patients treated with
inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), and montelukast (MON) (ICS/LABA/
MON) and patients treated with an inhaled corticosteroid (ICS) and montelukast (MON) (ICS/
MON).
Methods: This was a post-hoc analysis of a pretest-posttest retrospective cohort study. Patients
with mild persistent asthma and allergic rhinitis, who were taking an ICS either alone or in
combination with a LABA, started concomitant MON treatment as part of their routine care. Rates
of asthma- and allergic rhinitis-related medical resource use in the 12-months after the initial
(index) MON prescription were compared in the ICS/MON and ICS/LABA/MON groups. An
asthma attack was defined as an asthma-related hospitalization, E R  v i s i t ,  o r  u s e  o f  a n  o r a l
corticosteroid.
Results: Of the total of 344 patients, 181 (53%) received ICS/MON and 163 (47%) received ICS/
LABA/MON in the post-index period for means of 10.5 and 11.4 months, respectively, (P < 0.05).
Short-acting beta-agonists were used by 74.6% in the ICS/MON and 71.8% in the ICS/LABA/MON
groups (P > 0.05). An asthma attack occurred in 4.4% of the ICS/MON group and 6.8% of the ICS/
LABA/MON group (P > 0.05). The adjusted odds of an asthma attack in the post-index period in
the ICS/LABA/MON group relative to the ICS/MON group was 1.24, 95% confidence interval 0.35–
4.44.
Conclusion: In this observational study of combination drug treatment of mild persistent asthma
and allergic rhinitis, no difference was observed between LABA/ICS/MON combination therapy
and the ICS/MON combination without LABA use, for the rate of asthma attacks over one year.
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1. Background
The precise roles of drug combinations in the manage-
ment of asthma and allergic rhinitis remain uncertain [1].
The recommended maintenance therapies for persistent
asthma include inhaled corticosteroids (ICSs), leukot-
riene modifiers, and long-acting beta-agonists (LABAs).
ICSs are the preferred initial therapy for persistent asthma
[1]. Leukotriene modifiers, including montelukast
(MON), are recommended for mild persistent asthma, as
add-on therapy to ICSs for moderate persistent asthma, or
as an alternative maintenance therapy for patients unable
to tolerate ICSs [2,3], and are also effective against co-
morbid allergic rhinitis [4,5]. LABAs are recommended
only as add-on therapy to ICSs for moderate or severe
asthma, but not for mild persistent asthma or allergic
rhinitis, or as asthma monotherapy. Combinations of
more than two medication classes are recommended only
for severe persistent asthma. The 2006 GINA and 2007
NAEPP guidelines gave leukotriene modifiers a more
prominent role in the treatment of asthma, particularly
for those with concomitant allergic rhinitis, and restricted
use of LABAs because of safety concerns [2,3].
Although current asthma treatment guidelines recom-
mend ICS + LABA as the first line therapy for patients with
severe asthma, there are a lot of controversies [6,7] over
the potential safety issues [8] and an excess mortality rate
in some studies [9]. The main concern is that chronic
administration of LABAs may diminish the acute bron-
chodilating effect of short-acting beta-agonists [10-13],
thus leaving the patient vulnerable to acute asthma
attacks. Their use needs reappraisal [14], though LABAs
are still advocated when taken in combination with an
ICS [15]. However, there have been few observational
studies of patient outcomes from the use of LABAs in com-
bination with other long-term control asthma medica-
tions.
The PRAACTICAL (Patient-level Review of Asthma and
Allergy Care Therapy Including Current Asthma treatment
and Leukotrienes) study was a two-year retrospective pre-
posttest study designed to assess the role of MON when
added to an ICS in the treatment of patients with persist-
ent asthma and allergic rhinitis [16]. The addition of
MON was associated with reductions in asthma attacks,
defined as an Emergency Room (ER) visit, hospitalization,
or oral corticosteroid use for asthma. Since many patients
in PRAACTICAL also received LABAs, this study provided
an opportunity to assess outcomes in patients treated with
combinations of MON, ICSs compared to patients who
were treated with MON, ICSs and LABAs combination
therapy.
In PRAACTICAL, patient groups diagnosed with mild and
moderate asthma differed significantly in certain charac-
teristics: mean age (31.6 versus 34.0 years); proportion
with intermittent versus persistent allergic rhinitis (58.6%
versus 41.1%); and the proportion being treated with
LABAs on the index date (48.0% versus 84.2%). We ana-
lyzed the subgroup of patients having a physician's diag-
nosed with mild persistent asthma and concomitant
allergic rhinitis. The objective was to determine differ-
ences in the likelihood of asthma attacks in patients
treated with inhaled corticosteroid (ICS), long-acting
beta-agonist (LABA), and montelukast (MON) (ICS/
LABA/MON) and patients treated with an inhaled corti-
costeroid (ICS) and montelukast (MON) (ICS/MON).
2. Methods
2.1 Study overview
This was a post-hoc analysis of a cohort study of adults
15–55 years of age, with mild persistent asthma and con-
comitant allergic rhinitis, in three European countries
(Italy, Spain, and Poland) from January 1, 1998 to
December 31, 2003. Data were extracted from medical
records with the collaboration of patients' health care pro-
viders. Patients already being treated with ICSs were
included in the study if they began co-therapy with MON
as part of their routine care during an index period
between January 1, 1999 and December 31, 2002. Pre-
index and post-index periods of 12 months were defined
prior to and following the initial, index prescription for
MON. Patient characteristics in the 12-month pre-index
period were recorded and study outcomes were deter-
mined for the 12-month post-index period. Further
details of the study were described elsewhere [16]. Here,
we report a post hoc analysis of the subset of patients with
a physician diagnosis of mild persistent asthma, in which
two treatment groups, ICS/LABA/MON and ICS/MON,
were defined on the basis of their treatment in the post-
index period.
2.2 Patient population
Patients in this analysis: had physician-diagnosed mild
persistent asthma on the index date; had physician-diag-
nosed intermittent or persistent allergic rhinitis (these
terms replace the previous 'seasonal' and 'perennial'); had
prescription(s) for an ICS for at least 3 months during the
12-month post-index period, with or without a concomi-
tant prescription(s) for a LABA for at least 3 months in the
post-index period; started MON therapy as part of their
routine care; and completed 12 months of MON therapy
in the post-index period. The severities of asthma and sea-
sonal allergic rhinitis on the index date were determined
by physician diagnosis based on the GINA and ARIA
guidelines that were provided to ensure that all patients
had a diagnosis of mild persistent asthma on the index
date. This is an ad hoc retrospective analysis of data from
a cohort study, in which patients were asked to provide
informed consent that authorized investigators to reviewBMC Pulmonary Medicine 2009, 9:10 http://www.biomedcentral.com/1471-2466/9/10
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their charts when the original cohort study was con-
ducted.
2.3 Outcome measures
The study outcome variables were the numbers of pre-
scriptions for asthma-and allergic rhinitis-related medica-
tions (short-acting beta-agonists, oral corticosteroids,
antibiotics, and antihistamines) and numbers of asthma-
related hospitalizations and ER visits in the post-index
period. A composite endpoint, an 'asthma attack', was
defined as either use of an oral corticosteroid for asthma,
or an asthma-related ER visit or hospitalization.
2.4 Statistical analysis
Two parallel groups, ICS/LABA/MON and ICS/MON,
were defined on the basis of their treatment in the post-
index period. Uni-variable analyses were used to compare
the two treatment groups. T-test was used for continuous
data and the chi-square test for discrete data in the com-
parisons of patient characteristics in the pre-index period
and unadjusted study outcomes in the post-index period.
Multiple logistic regression was used to compute the
adjusted likelihood of asthma-and allergic rhinitis-related
health care use in the post-index period in the ICS/LABA/
MON group relative to ICS/MON group. Adjustments
were made for age, years of diagnosed allergic rhinitis,
severity of allergic rhinitis, number of allergist visits, days
on ICS or ICS/LABA treatment during the pre-index
period, and days of ICS or ICS/LABA treatment during the
post-index period. The analysis considered patients
treated for at least three months with an ICS or an ICS/
LABA combination in the post-index period (all patients
received 12 months of MON in the post-index period). A
p value of 0.05 was considered to be statistically signifi-
cant. All statistical analyses were performed using SAS
v8.2 (Cary, NC, USA).
3. Results
3.1 Patient characteristics
A total of 344 patients were included: 181 treated with
ICS/MON and 163 with ICS/LABA/MON. Most patients
had mild intermittent (36.1%) or mild persistent (46.8%)
allergic rhinitis (Table 1). Patients had spent an average of
10.8 months on ICS therapy in the pre-index period –
10.5 months in the ICS/MON group and 11.2 months in
the ICS/LABA/MON group. Patients in the ICS/LABA/
MON group had spent an average of 8.0 months on LABA
therapy in the pre-index period, while those in the ICS/
MON group had spent an average of 1.1 months. There
were no statistically significant differences between the
ICS/MON and ICS/LABA/MON groups in most character-
istics. Compared with patients in the ICS/MON group,
however, those in the ICS/LABA/MON group were slightly
older (32.6 versus 30.4 years), had been diagnosed with
allergic rhinitis for fewer years (8.4 versus 10.7 years), had
more months on ICS therapy in the pre-index period
(11.2 versus 10.5 months), and were less likely to visit an
allergist in the post-index period (33.1% versus 47.0%).
Finally, compared with patients in the ICS/MON group,
those in the ICS/LABA/MON group had more months on
therapy in the post-index period (11.2 versus 10.4
months).
3.2 Asthma- and allergic rhinitis-related medical resource 
utilization in the post-index period
Rates of medical resource use for asthma and allergic rhin-
itis in the 12-month post-index period were not signifi-
cantly different in the ICS/MON and ICS/LABA/MON
groups (Table 2). An asthma attack occurred in 4.4% of
the ICS/MON group and 6.8% of the ICS/LABA/MON
group. The adjusted likelihood of asthma and allergy
medication use in the post-index period was not statisti-
cally significantly different in the ICS/LABA/MON and
ICS/MON groups (Table 3). The likelihood of antibiotic
use, however, was statistically significantly greater in the
ICS/LABA/MON group (p = 0.031; Wald χ2 test). The like-
lihood of an ER visit or of occurrence of an asthma attack
was similar in the ICS/MON and ICS/LABA/MON groups
(hospitalizations were too infrequent to be analyzed as a
single independent variable).
4. Discussion
Meta-analyses of clinical trials indicate that the anti-asth-
matic effects of both leukotriene modifiers and LABAs are
additive to those of ICSs [17,18]. Clinical trials have not
demonstrated additivity of the effects of LABAs and leuko-
triene modifiers on asthma symptoms, though addition
of MON to ICS/LABA therapy reduces symptoms of aller-
gic rhinitis [19,20], and the addition of MON to a LABA
or ICS/LABA combination improves airway hyperrespon-
siveness to methacholine or adenosine monophospate
challenge [21,22].
The results of this study should be interpreted in the light
of the following. The absence of an incremental effect of
LABAs was inferred from the comparison of two parallel
treatment groups. This study compared differences in the
asthma-related outcomes of various combinations of
asthma therapy (specifically ICS/LABA/MON vs ICS/
MON). Patients in the two groups differed in certain
respects: patients in the ICS/MON/LABA group had
slightly longer durations of ICS therapy in the pre-index
and post-index periods, and appeared to have a lesser bur-
den of allergic rhinitis (the elapsed time since diagnosis of
allergic rhinitis was shorter, and the likelihood of visiting
an allergist in the pre-index period was lower). We
adjusted for differences between the two patient groups by
multivariate regression modeling. Patients in the ICS/
MON/LABA group had a greater adjusted odds of using
antibiotics in the post-index period, presumably reflectingBMC Pulmonary Medicine 2009, 9:10 http://www.biomedcentral.com/1471-2466/9/10
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Table 1: Patient characteristics*
ICS/MON ICS/LABA/MON All Patients
Patient N (%) 181 (52.6%) 163 (47.4%) 344 (100.0%)
Years of age‡ 30.4 ± 9.3 32.6 ± 9.4 31.5 ± 9.4
Male sex 82 (45.3%) 69 (42.6%) 151 (44.0%)
Current smoker 6 (3.3%) 10 (6.1%) 16 (4.7%)
Years since asthma diagnosed 8.5 ± 7.6 8.0 ± 7.7 8.3 ± 7.7
Years since allergic rhinitis diagnosed‡ 10.7 ± 8.2 8.4 ± 7.7 9.6 ± 8.1
Allergic rhinitis severity
Mild intermittent 60 (33.2%) 64 (39.3%) 124 (36.1%)
Mild persistent 87 (48.1%) 74 (45.4%) 161 (46.8%)
Moderate-severe intermittent 26 (14.4%) 15 (9.2%) 41 (11.9%)
Moderate-severe persistent 8 (4.4%) 10 (6.1%) 18 (5.2%)
Months on therapy in prior 12 months
ICS‡ 10.5 ± 3.4 11.2 ± 2.4 10.8 ± 3.0
ICS/LABA‡ 1.1 ± 3.2 8.0 ± 5.2 4.4 ± 5.5
Asthma- and allergic rhinitis-related medical resource use in prior 12 months
Short-acting beta-agonist 155 (85.6%) 130 (79.8%) 285 (82.9%)
Oral corticosteroids 21 (11.6%) 24 (14.7%) 45 (13.1%)
Antibiotics 38 (21.0%) 44 (27.0%) 82 (23.8%)
Antihistamines 129 (71.3%) 104 (63.8%) 233 (67.7%)
Allergist visit‡ 85 (47.0%) 54 (33.1%) 139 (40.4%)
Pulmonologist visit 1 (0.6%) 1 (0.6%) 2 (0.6%)
Emergency Room visit 34 (18.8%) 23 (14.1%) 57 (16.6%)
Hospitalization 7 (3.9%) 3 (1.8%) 10 (2.9%)
Asthma attack† 49 (27.1%) 44 (27.0%) 93 (27.0%)
Months on therapy in 12-month follow-up‡ 10.5 ± 2.9 11.4 ± 1.9 10.9 ± 2.5
*Values represent patient N (%) or mean ± SD. † An asthma attack was defined as use of an oral corticosteroid, an asthma-related ER visit, or an 
asthma-related hospitalization. ‡ p < 0.05 for ICS/MON compared with ICS/LABA/MON.BMC Pulmonary Medicine 2009, 9:10 http://www.biomedcentral.com/1471-2466/9/10
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inappropriate prescribing and a perceived need for addi-
tional therapies in these patients. Although small, the pro-
portion of asthma attacks differed in the two groups with
the ICS/LABA/MON group experiencing more as com-
pared to ICS/MON group. Data from this study provided
evidence of differences between the two therapy groups.
Due to the rare occurrence of asthma attacks, studies with
larger sample sizes are needed to confirm our findings.
5. Conclusion
Based on this observational study, patients with comorbid
asthma and allergic rhinitis receiving ICS/MON combina-
tion therapy, and those receiving ICS/MON/LABA combi-
nation therapy had similar rates of asthma attacks.
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